ASCO GU 2025

What's the role of Enzalutamide in radioligand therapy?

Combining ARPi with PARPi - discussing final OS of TALAPRO-2

Milestones of ADT and ARPI treatment in the metastastic prostate cancer

Durvalumab in UTUC

Radical Prostatectomy VS RT in HRPC

ENZA-p showed OS benefit and improvement in QoL parameters

ARPI for which patients?

Testosterone Recovery

Who benefits most from ARPIs?

Testosterone Recovery after ADT and OS

MDT in OMPC

Radiation vs surgery in high risk prostate cancer

Final OS analyses

Final OS data for TALA + Enza

OS in the TALAPRO-2 trial

Darolutamide + ADT and Doetaxel improves survivas in mHSPC across age groups

Mevrometostat - a new EZH2 inhibitor in mCRPC

Fish-oil supplement for pts on active surveillance

Phase 2 Mevrometostat

Local radiotherapy of oligoprogressive mCRPC

Hypo-gonadism bad for survival?

Darolutamide + ADT reduces risk of progression or death by 46 % in mHSPC

Mevrometostat + Enza: New option for mCRPC

Improved Survival with Enzalutamide + Lutetium

Yuksek risk PCa da RP vs RT

Testosteron Geri Gelisi ve Sagkalim

Enza+Lu ile artmis sagkalim

UTUC de Neoadj. Durvalumab+Kemo

Oligometastatik PCa da MDT

Hangi hastalarda ADT+ARPI

New data but no new conclusion

Exciting new substances - but don't over-estimate phase 1 data

Triplet combination in RCC - there's no free lunch with VEGFR

KIM-1 - The most interesting biomarker for RCC?

Casdatifan in refracting RCC

KIM-1 in CheckMate 214

Firstline Update Kidney Cancer

New agents / new mode of actions

Advanced Renal Cell Cancer: Adding more drugs does not translate in greater benefit

KIM-1 in mRCC

Prognostic and predictive biomarkers in mRCC: Looking for the holy grail

Proactive coaching of patients with TKI +/- IO therapy

AVION trial at mRCC

New data nccRCC

Cáncer de células renales avanzado: añadir más fármacos no se traduce en un mayor beneficio

Biomarcadores prognósticos y predictivos en el CCRm: en busca del Santo Grial

Exploratory analyses of pCR in NIAGARA: who benefits most from perioperative Durvalumab?

Reassuring data on established ADCs and new insights in novel ADCs for urothelial cancer

Neoadjuvant chemo-immunotherapy in UTUC: new evidence for a challenging indication

New data, but no new insights for adjuvant treatment of high-risk MIBC patients

ADC + ICI - The future for MIBC?

Phase 2 Mevrometastat

New drugs in mUC: The active field of ADCs

Updates neo/adjuvant therapy in MIBC

Sacituzumab Tirumotecan shows promising antitumor activity in aUC after platinum-based therapy

Durvalumab + Platinum-based chemotherapy shows promising efficacy and safety in high-grade UTUC

ASCO GU 25 - Summary: Urothelial Cancer

New FGFR3 inhibitor

Preliminary results of neoadjuvant chemoimmunotherapy in UTUC

Nivo adjuvant in MIBC - a new standard

Adjuvant Nivo - independent from previous therapy

Neoadjuvant treatment for UTUC

Bladder-sparing approaches - are we there yet?

A possible new standard for mUC

The role of ctDNA in bladder cancer

EV-Pembro continues to be the standard for mTCC

HER2 - new marker for bladder preservation

Promising combination for perioperative setting

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

Promising combination for perioperative setting

Nuevos fármacos en mUC: El campo activo de las ADCs

RPLND in metastatic Seminoma

Testicular cancer: Reinventing the wheel

Metastatik seminomda Primer RPLND

Cáncer de testículo: reinventar la rueda